3 Companies Join Forces to Test Personalized ‘Teaching’ Vaccine for Ovarian Cancer

3 Companies Join Forces to Test Personalized ‘Teaching’ Vaccine for Ovarian Cancer
TransGene, NEC, and BostonGene have entered a strategic collaboration to test TG4050, an investigational personalized vaccine that aims to treat ovarian and head and neck cancers, according to a press release. TG4050 is an individualized therapy that stimulates a patient's immune system into attacking cancer cells by "teaching" it which cells are malignant — based on the presence of certain mutated cancer proteins, called neoantigens, found in tumor tissues. The partners will first use NEC's artificial intelligence-based neoantigen prediction system, which is able to find specific mutations that are present on a patient’s tumor and not in the normal genome. The AI-based system will predict which neoantigens will elicit the strongest immune responses. Then, using TransGene's myvac platform, a harmless virus is packed with the genetic instructions for up to 30 of these neoantigens, and injected subcutaneously (under the skin). The approach tells the immune system that it should target
Subscribe or to access all post and page content.